Swedish researchers first in the world to gain access to the Biobank Information Management System (BIMS)
Owing to the system now being developed at Karolinska Institutet in Stockholm, the university's biobank will now be based on informatics as well as tissue and blood samples. The system will enable researchers to seek biobank samples linked to the vast databases of phenotype and genotype information on the individual donors and to a variety of other data sources.
The existence of large national epidemiological databases, such as the Swedish twin register, and a large number of tissue sample collections of national importance gives the Karolinska Institutet Biobank a unique position in biobank-related research. Since the information is highly sensitive and authorised data access unacceptable, the biobank system is protected by tight security.
"We're the first institute in the world with such an informatics system," says Professor Jan-Eric Litton of the Department of Medical Epidemiology and Biostatistics. "Other prominent medical centres like the Mayo Clinic in the USA are also developing similar systems."
The establishment of the BIMS informatics system is a strategic investment at KI to support and enable future advanced clinical research. It makes it easier to find causes, diagnostic tools and cures for diseases by allowing more research scientists and research fields to make use of huge amounts of connectable data; something which will be of immense value to the next generation of research scientists.
"The main advantage is that researchers can save time and access information without having to be specialists in the area," says Professor Litton. "So in other words they can search in English in all databanks and get comprehensible responses."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
International_Medical_Informatics_Association

Merck Expands Production Know-how to Deliver Full End-To-End Solution for Biopharma Industry - Flexible factory concept allows accelerated drug development and delivery to market
Archibald_Hill
Haplogroup_R2_(Y-DNA)

How an Emerging Drug Class Dampens Harmful Immune Reactions - It wasn't until 2021 that a new therapy came on the market, in the form of a class of drugs called compstatins, to inhibit harmful immune responses of the complement system
Haplogroup_O2a_(Y-DNA)
